Thrombocytopenia

Argatroban reduces thrombosis, death due to thrombosis

Published in Blood Weekly, September 11th, 2003

The largest prospective study of patients with heparin-induced thrombocytopenia (HIT), a potentially severe reaction to heparin, showed that the direct thrombin inhibitor Argatroban significantly reduced thrombosis (clots) and deaths due to thrombosis without increasing the risk of bleeding, according to an article published in the Archives of Internal Medicine.

The multicenter investigation compared 418 patients to 185 historical controls. Notable improvements were demonstrated in the Argatroban-treated patients with HIT in a composite endpoint that included death due to all causes, amputation due to all causes or new thrombosis formation.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-09-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry